About Kinnos

Jason Kang is the Chief Executive Officer and a co-founder of Kinnos. Jason previously conducted biomedical research at Harvard Medical School and Columbia University and served as the VP of Engineering at Jibon Health Technologies, where he brought a medical device to clinical trials in Bangladesh. For his pioneering work, Jason has been named to Forbes 30 Under 30 in Healthcare, served as a AAAS-Lemelson Invention Ambassador, recognized as a Bluhm/Helfand Social Innovation Fellow, and selected as one of Crain’s New York Business Notable Leaders in Health Care. Jason studied Biomedical Engineering at Columbia University as an Egleston Scholar and recently served on the Executive Board of Columbia Engineering Young Alumni.

‍

Melissa Comunale is the founder and Principal of Movi Consulting, a boutique firm specializing in commercialization and advisory services to early-stage MedTech organizations. Melissa has successfully built and led commercial field teams to launch disruptive technologies across multiple healthcare specialties including Spine, Orthopaedics, Plastic Surgery, Breast Cancer, Vascular Access, ENT, and Infection Prevention. She has held domestic and international sales and marketing roles at both global and early-stage MedTech and health care organizations including Stryker, Baxter, and Invuity, acquired by Stryker (NYSE: SYK). Melissa has dedicated the most recent decade of her career exclusively to early-stage organizations with novel technologies. Prior to launching Movi, Melissa was the Vice President of Sales at Velano Vascular, acquired by Becton Dickinson (NYSE: BDX) in 2021, where she led the sales organization to launch revolutionary needle-free inpatient blood draws as a more humane standard of care. She excels in commercial strategy, sales operations, go-to-market development, sales training, executive coaching, and serves as an integral cross-functional and motivational leader. She is fluent in Spanish and earned an MBA, Master of Science in Health and Human Performance, and Bachelor's Degree in Business Administration, cum laude, from the University of Florida. Melissa resides with her husband and two children in Windermere, Florida.

‍

‍

A seasoned senior executive with broad operational experience, Quinton has served in executive roles for over 25 years and has more than 35 years of medical device experience. While leading West Surry Strategies LLC he also served as Senior Vice President of Technical Operations R&D/RA/QA/Operations for Velano Vascular for the 6 years leading up to the acquisition by Becton-Dickinson. Prior to founding West Surry, he was the Global VP of Operations Technology and R&D at Smiths Medical. At Smiths he led the effort to increase OI from 18% to 25% and increased new product from 3% to 14% of sales. Prior to joining Smiths, Quinton was the Sr. VP Technology Development/RA/QA with Genzyme Biosurgical. He joined Genzyme when they acquired the privately held medical device manufacturer Deknatel Snowden-Pencer where he was the Executive VP of Technology Development. Quinton had a leadership role in taking this firm private during a management buyout from Pfizer Hospital Products. During his tenure with the Pfizer Division, Deknatel, he served as a Project Engineer, Director, and VP of Product Development as well as the Group VP of Blood Recovery. Quinton started his medical device career at NMC and progressed to BD. He has more than 30 patents and developed more than 100 cleared devices.

‍

‍

Katherine Jin double-majored in Biology and Computer Science as a Coca-Cola Scholar at Columbia University. Katherine has worked in the Trauma Center and as a clinical researcher at Mount Sinai St. Luke's Hospital, and has conducted research at the Carnegie Institute of Washington and Columbia University. While at Columbia, Katherine served as Campus Coordinator of the Harlem Hospital Chapter of Health Leads. Katherine has been featured by the United Nations in celebration of International Day of Women and Girls in Science and was named to the inaugural list of The Tempest's #40WomentoWatch.

‍

Son Pham has over 20 years of financial management experience in both publicly-traded and privately-held companies. He brings broad perspectives and best practices accumulated from different industries that include life sciences, energy and power, food and agriculture, e-commerce, semiconductor, and financial services. He has extensive experience working in early- and growth-stage companies, where he excels at building finance and accounting functions from the ground up or upleveling existing infrastructure and talent. In later stage companies, he is adept at scaling processes and systems, building and owning financial models, and aligning organizations around a consistent set of plans and assumptions. He has participated in over $100M of equity and debt financings and completed multiple buy-side acquisitions, sell-side exits, M&A integrations, and divestitures.

‍

Prior to Kinnos, Son worked in the e-commerce sector as the CFO of Farmgirl Flowers, Inc, an online retailer, where he built out the company’s first finance and accounting function. Prior to Farmgirl Flowers, he was the Vice President of Finance and Administration of Velano Vascular, Inc., a private medical technology company, where he eventually assisted in its acquisition by Becton, Dickinson and Company (NYSE: BDX) in 2021. Prior to Velano Vascular, Son held various financial and operational director roles at VoloAgri Group, Inc., an agricultural technology company and First Solar, Inc. (NASDAQ: FSLR), where he helped develop and sell some of the largest solar power plants in the U.S. Son began his career at National Semiconductor, which is now a division of Texas Instruments Inc., before moving to a client-serving role at Ernst & Young, LLP. He earned a B.S. in Business Administration from the University of California, Berkeley’s Walter A. Haas School of Business.

‍

‍

Suzanne M. Thompson is a recognized executive in the cleaning and hygiene industry with a reputation for transforming organizations, and balancing technology and innovation orientation with operations. Today she is helping companies improve their results from innovation, and commercialize and monetize new technology to transform their business.

‍

Suzanne Thompson was the R&D leader and Chief Technology Officer for Diversey for 6 years. Prior to that she was at Clorox for 29 years where she held a variety of R&D and regulatory roles. Suzanne was on the American Cleaning Institute board of directors for 4 years and was on the Product Development Management Association board of directors for 6 years where she led the selection committee for the Outstanding Corporate Innovator program.  

‍

Suzanne has a Bachelor’s degree in Chemical Engineering from MIT and a Masters degree in Chemical Engineering from UC Berkeley.

‍

Jason Kang is the Chief Executive Officer and a co-founder of Kinnos. Jason previously conducted biomedical research at Harvard Medical School and Columbia University and served as the VP of Engineering at Jibon Health Technologies, where he brought a medical device to clinical trials in Bangladesh. For his pioneering work, Jason has been named to Forbes 30 Under 30 in Healthcare, served as a AAAS-Lemelson Invention Ambassador, recognized as a Bluhm/Helfand Social Innovation Fellow, and selected as one of Crain’s New York Business Notable Leaders in Health Care. Jason studied Biomedical Engineering at Columbia University as an Egleston Scholar and recently served on the Executive Board of Columbia Engineering Young Alumni.

Ms. Larkin was appointed to the Board of Directors in September 2023. She is a former senior executive of Assertio Therapeutics, Inc., having retired in 2020 as senior vice president (SVP) Human Resources and Administration.

‍

Ms. Larkin joined Assertio Therapeutics, Inc. in 2017 after retiring from Abbott in 2015 as divisional vice president (DVP), Human Resources, Medical Devices Group, where she provided global human resources leadership for Abbott’s five medical device operating businesses, including Abbott Diabetes Care, Abbott Vascular, Abbott Medical Optics, Abbott Animal Health and Abbott Electrophysiology. Ms. Larkin joined Abbott in 1992 and also held positions of increased responsibility in Abbott’s Nutrition, HealthSystems and Corporate operations.

‍

Prior to joining Abbott, Ms. Larkin worked for the Federal Reserve Bank of Atlanta, Jacksonville Branch, where she provided leadership for the branch’s U.S. Treasury securities services and human resources operations. Ms. Larkin holds a bachelor’s of science in Industrial Management from the Georgia Institute of Technology.

‍

Other public board membership includes: Senseonics, Incorporated

‍

Eric M. Stone served most recently as Chief Executive Officer and co-founder of Velano Vascular, a pioneering medical technology company that conducted 2 million annual inpatient procedures prior to its acquisition by Becton Dickinson (NYSE: BDX) in 2021. Under Stone’s leadership, Velano was named to Fast Company’s Most Innovative Companies list, Inc. 5000 Fastest Growing Private Companies (#347), Fierce15 Medtech, Deloitte Fast 500, and Real Leaders 100 Leading Impact Companies. Prior to Velano, he served in commercial leadership roles with Molecular Health and Abbott Labs (NYSE: ABT) in the U.S. and abroad and was a founding member of Model Nʼs (NYSE: MODN) Life Sciences business. He was also a marketing and organizational change consultant, and began his career with Trilogy Software. Stone co-founded social sector programs at Harvard and Wharton and served for a decade on Harvard Universityʼs Alumni Association (HAA) Board of Directors, as well as a former National Trustee and Executive Committee member of the Crohn’s and Colitis Foundation. Today, he serves as Director, Advisor and investor in several healthcare companies, is an Advisor to Kapor Capital, and a member of YPO Northern California. In 2021 Stone was named an Ernst & Young Entrepreneur of the Year for Northern California. He received an MBA in Health Care Management from The Wharton School, a Masterʼs from Harvard University, and a BA from the University of Pennsylvania. Stone lives with his wife and two children in Chicago, Illinois.

Bob has led eleven different healthcare and technology businesses as President or CEO, ranging in size from early stage to over $5B in annual revenue. He was the Chairman and CEO at Vocera, a publicly traded HCIT company that was recently sold to Stryker. Prior to that Bob served as the CEO of Wound Care Solutions which was merged into Healogics. Bob led Neoforma prior to that as Chairman and CEO, taking the company public and ultimately selling it to Global Health Exchange. Bob was EVP, Group President at Cardinal Health responsible for five of their wholly owned subsidiaries: Pyxis, Owen Healthcare, Medicine Shoppe, as well as their IT and International businesses. Before Cardinal, Bob led four different operating divisions of Baxter including Dietary Products, Scientific Products, IV Therapy, and US Distribution. He held a number of positions with American Hospital Supply Corporation before that company was acquired by Baxter. Bob joined Frazier Healthcare Partners as an Operating Partner in their Growth Equity business in 2015 and has chaired three Frazier portfolio company Boards: Leiters, AppianRx, and Parata Systems. He is currently a Senior Advisor to Frazier. Bob has served on over 20 corporate boards, and currently serves on the boards of Five9, Kate Farms, Recuro Health, Cubex, and Kinnos. He is a Board Fellow with the National Association of Corporate Directors (NACD) and also serves as a Trustee of Arizona State University.